List of Azstarys drug patents

Azstarys is owned by Commave Therap.

Azstarys contains Dexmethylphenidate Hydrochloride; Serdexmethylphenidate Chloride.

Azstarys has a total of 6 drug patents out of which 0 drug patents have expired.

Azstarys was authorised for market use on 07 May, 2021.

Azstarys is available in capsule;oral dosage forms.

Azstarys can be used as treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate.

Drug patent challenges can be filed against Azstarys from 2025-05-07.

The generics of Azstarys are possible to be released after 09 December, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10584112 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079928 COMMAVE THERAP Methylphenidate-oxoacid conjugates, processes of making and using the same
Jul, 2032

(9 years from now)

US10858341 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

US10954213 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

US10584113 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

US10759778 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 7, 2026

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

NCE-1 date: 2025-05-07

Market Authorisation Date: 07 May, 2021

Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate

Dosage: CAPSULE;ORAL

More Information on Dosage

AZSTARYS family patents

23

United States

7

Israel

6

Korea, Republic of

5

Japan

4

Mexico

4

Canada

3

Australia

3

China

3

European Union

2

Brazil

2

Spain

2

New Zealand

1

South Africa

1

Denmark

1

Slovenia

1

Lithuania

1

Russia

1

Hungary

1

Argentina

1

Singapore

1

Croatia

1

Colombia

1

Portugal

1

Malaysia

1

Poland

1

Chile

1

RS

1

Ukraine

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic